Literature DB >> 7718226

Effects of human middle ear effusions on the mucociliary system of the tubotympanum in the guinea pig.

Y Ohashi1, Y Nakai, Y Ohno, Y Sugiura, H Okamoto.   

Abstract

Effusion fluid resulting from otitis media contains a variety of inflammatory substances. This middle ear effusion (MEE) may be itself affect the mucosa of the tubotympanum and contribute to chronicity of the condition. The present study was designed to elucidate in vitro and in vivo effects of MEEs on the mucosa of the guinea pig tubotympanum. The results obtained demonstrated that the ciliary activity of the eustachian tube was reduced in the presence of human MEEs. This activity decreased to approximately 80% in the presence of serous MEE at 48 h and was 60% after exposure to mucoid MEE. Intratympanic inoculation of human MEEs resulted in accumulation of a serous effusion in the tympanic cavity. Histologic study of the tubotympanum in inoculated animals demonstrated mucociliary dysfunction as well as a general inflammatory process and increased vascular permeability. This damage was more prominent following inoculation with the mucoid MEEs. The ciliary depression and inflammation found in the tubotympanum suggest that the pathologic nature of MEEs may be, at least partially, responsible for the chronicity of otitis media.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7718226     DOI: 10.1007/bf00171438

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  14 in total

1.  Ciliary activity in the in vitro tubotympanum.

Authors:  Y Ohashi; Y Nakai; H Koshimo; Y Esaki
Journal:  Arch Otorhinolaryngol       Date:  1986

2.  Culture of normal human leukocytes.

Authors:  G E Moore; R E Gerner; H A Franklin
Journal:  JAMA       Date:  1967-02-20       Impact factor: 56.272

3.  Ciliary activity of the middle ear lining in guinea pigs.

Authors:  Y Ohashi; Y Nakai; S Kihara
Journal:  Ann Otol Rhinol Laryngol       Date:  1985 Jul-Aug       Impact factor: 1.547

Review 4.  Current concepts of mucociliary dysfunction in otitis media with effusion.

Authors:  Y Ohashi; Y Nakai
Journal:  Acta Otolaryngol Suppl       Date:  1991

5.  Influenza A virus-induced otitis media and mucociliary dysfunction in the guinea pig.

Authors:  Y Ohashi; Y Nakai; Y Esaki; Y Ohno; Y Sugiura; H Okamoto
Journal:  Acta Otolaryngol Suppl       Date:  1991

6.  Histamine-induced mucociliary dysfunction and otitis media with effusion.

Authors:  Y Esaki; Y Ohashi; H Furuya; Y Sugiura; Y Ohno; H Okamoto; Y Nakai
Journal:  Acta Otolaryngol Suppl       Date:  1991

7.  Histamine levels in middle ear effusions.

Authors:  G Berger; M Hawke; D W Proops; N S Ranadive; D Wong
Journal:  Acta Otolaryngol       Date:  1984 Nov-Dec       Impact factor: 1.494

8.  Endotoxin in middle-ear effusions from patients with chronic otitis media with effusion.

Authors:  T F DeMaria; R B Prior; B R Briggs; D J Lim; H G Birck
Journal:  J Clin Microbiol       Date:  1984-07       Impact factor: 5.948

9.  Quantitative determination of bacterial endotoxin in middle ear effusions by chromogenic substrate method.

Authors:  T Jinnin; Y Dake; T Kusumoto; T Tabata
Journal:  Auris Nasus Larynx       Date:  1985       Impact factor: 1.863

10.  Mucociliary function in children with secretory otitis media.

Authors:  J Kärjä; J Nuutinen; P Karjalainen
Journal:  Acta Otolaryngol       Date:  1983 May-Jun       Impact factor: 1.494

View more
  2 in total

Review 1.  What have we learned from murine models of otitis media?

Authors:  Hayley E Tyrer; Michael Crompton; Mahmood F Bhutta
Journal:  Curr Allergy Asthma Rep       Date:  2013-10       Impact factor: 4.806

2.  The role of inflammatory mediators in the pathogenesis of otitis media and sequelae.

Authors:  Steven K Juhn; Min-Kyo Jung; Mark D Hoffman; Brian R Drew; Diego A Preciado; Nicholas J Sausen; Timothy T K Jung; Bo Hyung Kim; Sang-Yoo Park; Jizhen Lin; Frank G Ondrey; David R Mains; Tina Huang
Journal:  Clin Exp Otorhinolaryngol       Date:  2008-09-30       Impact factor: 3.372

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.